Ruojing Li

Ruojing Li is currently the Director of Quantitative Pharmacology and Pharmacometrics at Merck, specializing in immune and oncology therapies. They received a B.S. in Pharmaceutical Sciences and an M.Sc. in Pharmaceutics from Peking University in China, followed by a Ph.D. in Pharmacology from Johns Hopkins University School of Medicine. Previously, Ruojing served as a Clinical Pharmacology Team Leader at the FDA, where they led clinical pharmacology reviews and contributed to regulatory decision-making for clinical development. They have extensive expertise in population pharmacokinetics, pharmacodynamics modeling, and various advanced analytical tools, alongside a strong background in team management and FDA guidance development.